Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease

Immunological Reviews

Volumn 157, Issue , 1997, Pages 111-123

  Hess, Allan D ^a   Thoburn, Christopher J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

AUTOIMMUNITY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; GRAFT VERSUS HOST REACTION; IMMUNOBIOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; T LYMPHOCYTE;

ANIMALS; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY; TRANSPLANTATION, ISOGENEIC;

EID: 0030754890     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb00977.x     Document Type: Review

References (102)

1. Santos GW, Hess AD, Vogelsang GB. Graft-versus-host disease. Immunol Rev 1985;88:169-192.
2. Vogelsang GB, Hess AD. Graft-versus-host disease: new directions for a persistent problem. Blood 1994;84:2061-2067.
3. Holler E, Ferrara JLM. Antagonists of inflammatory cytokines: prophylactic and therapeutic applications. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs-host disease. New York: Marcel Dekker; 1996. p. 667-692.
4. Gluckman E, Devergie A, Sohier J, Sauret JH. Graft-versus-host disease in recipients of syngeneic bone marrow. Lancet 1980;1:253-255.
5. Rappeport J, Reinherz E, Mihm M, Lopanski S, Parkman R. Acute graft-versus-host disease in recipients of bone marrow transplantation from identical twin donors. Lancet 1979;2:717-718.
6. Thien SW Goldman JM, Gallon DG. Acute "graft-versus-host disease" after autografting for chronic granulocytic leukemia in transplantation. Ann Intern Med 1981;94:210-214.
7. Hood AF, Vogelsang GB, Black LP, Farmer ER, Santos GW. Acute graft-versus-host disease. Development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987;123:745-750.
8. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect 1966-1967;62:21-78.
9. Santos GW, Elfenbein GJ, Sharkis S, Tutschka PJ. Reconstitution of lymphohematopoietic function following allogeneic, syngeneic, and autologous marrow transplantation. In: Gelfand EW, Dorsch HM, eds. Advances in pediatric research. I. Biological basis of immunodeficiency. New York: Raven Press; 1979. p. 293-314.
10. Glazier A, Tutschka PJ, Farmer ER, Santos GW. Graft-versus-host disease in cyclosporin A treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med 1983;158:1-8.
11. Glazier A, Tutschka PJ, Farmer ER. Studies on the immunobiology of syngeneic and autologous graft-versus-host disease in cyclosporine treated rats. Transplant Proc 1983;15:3035-3039.
12. Kahan BD. Cyclosporine. N Engl J Med 1989;21:1725-1738.
13. Morris PJ. Cyclosporin A. Transplantation 1981;32:349-354.
14. Borel JF. Pharmacology of cyclosporine IV. Pharmacological properties in vivo. Pharmacol Rev 1989;41:259-371.
15. Santos GW, et al. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-vs-host disease: a randomized double blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987;1:21-28.
16. Beschorner WE, Shin CA, Fischer A, Santos GW, Hess AD. Cyclosporine (CSA) induced pseudo-graft-vs-host disease (CIPGVHD) in the early post CsA period. Transplantation 1988;46(Suppl):112-117.
17. + T lymphocyte subsets. J Immunol 1990;140:526-533.
18. Beschorner WE, Tutschka PJ, Santos GW. Sequential morphology of graft-versus-host disease in the rat radiation chimera. Clin Immunol Immunopathol 1982;22: 203-224.
19. Korngold R, Sprent J. T-cell subsets in graft-vs-host disease. In: Burakoff SJ, Deeg HJ, Ferrara JLM, Atkinson K, eds. Graft-vs-host disease. Hematology 1990;12:31-49.
20. Bos GM, Major GD, Van Breda-Vriesman PJ. Cyclosporin-A induces a selective, reversible suppression of T-helper lymphocyte regeneration after syngeneic bone marrow transplantation: association with syngeneic graft-versus-host disease in rat. Clin Exp Immunol 1988;74:443-448.
21. Fischer AC, Laulis MK, Horwitz L, Hess AD. Effect of cyclosporine on T lymphocyte development: relationship to syngeneic graft-versus-host disease. Transplantation 1991;51:252-259.
22. Urdahl KB, Pardoll DM, Jenkins MK. Self-reactive T cells are present in the peripheral lymphoid tissues of Cyclosporin A-treated mice. Int Immunol 1992;4:1341-1349.
23. Parkman R. Clonal analysis of murine graft-versus-host disease. 1. Phenotypic and functional analysis of T lymphocyte clones. J Immunol 1985;136:3542-3549.
24. Parkman R. Clonal analysis of graft-vs-host disease. In: Burakoff SJ, Deeg HJ, Ferrara JLM, Atkinson K. Graft-vs-host disease. Hematology 1990;12:51-60.
25. Gajewski TF, Schell SR, Fitch FW. Evidence implicating utilization of different T-cell receptor associated signalling pathways by Th1 and Th2 clones. J Immunol 1990;144:4110-4120.
26. Fischer AC, et al. Characterization of the autoreactive T cell repertoire in cyclosporine-induced syngeneic graft-vs-host disease: a highly conserved repertoire mediates autoaggression. J Immunol 1995;154:3713-3725.
27. Cheney RT, Sprent J. Capacity of cyclosporine to induce autograft-versus-host disease and impair intrathymic T-cell differentiation. Transplant Proc 1985;17:528-530.
28. Shinozawa T, Beschorner WE, Hess AD. Prolonged administration of cyclosporine and the thymus: Irreversible immunopathologic changes associated with autologous pseudo-graft-vs-host disease. Transplantation 1990;50:106-111.
29. Beschorner WE, Ren H, Phillips J, Pulido HB, Hruban R, Hess AD. Recovery of thymic microenvironment after cyclosporine prevents syngeneic graft-vs-host disease. Transplantation 1991;52:668-674.
30. Beschorner WE, DiGennaro KA, Hess AD, Santos GW. Cyclosporine A (CsA) and the thymus: immunopathology and recovery. Cell Immunol 1988;110:350-364.
31. Surokin R, Kimura H, Schroder K, Wilson D. Cyclosporine-induced autoimmunity: conditions for expressing disease, requirement for intact thymus, and potency estimates of autoimmune lymphocytes in drug-treated rats. J Exp Med 1986;164:1615-1616.
32. Beschorner WE, Hess AD, Shinn CA, Santos GW. Transfer of cyclosporine-associated syngeneic graft-vs-host disease by thymocytes. Transplantation 1988;45:209-215.
33. Ryffel B, Deysseroth R, Borel JF. Cyclosporin A: effects on the mouse thymus. Agents Actions Suppl 1981;11:373-381.
34. Beschorner WE, Namnoum JD, Hess AD, Shinn C, Santos GW. Cyclosporin A and the thymus. Immunopathology. Am J Pathol 1987;126:487-496.
35. Fabien NH, et al. Effects of cyclosporin A on mouse thymus: immunochemical and ultrastructural studies. Thymus 1992;20:153-162.
36. Beschorner WE, Suresch DL, Shinozawa T, Hess AD. Influence of irradiation and age on the CsA induced thymic immunopathology. Transplant Proc 1988;20(Suppl 3):1072-1078.
37. Hess AD, Horwitz L, Beschorner WE, Santos GW. Development of graft-vs-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T-lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 1985;161:718-730.
38. Gao EK, Lo D, Cheney R, Kanagawa O, Sprent J. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988;336:176-179.
39. Hess AD, Vogelsang GB, Heyd J, Beschorner WE. Cyclosporine induced syngeneic graft-vs-host disease; assessment of T cell differentiation. Transplant Proc 1987;19:2683-2686.
40. Urdahl KB, Pardoll DM, Jenkins MK. Cyclosporin A inhibits positive selection and delays negative selection in γβ TcR transgenic mice. J Immunol 1994;152:2853-2859.
41. Severino ME, Laulis MK, Horwitz LR, Hess AD. Cyclosporine preferentially inhibits clonal deletion of CD8 positive T-cells with an MHC class II restricted autoreactive T-cell receptor. Transplantation 1993;25:520-523.
42. Zadeh HH, Goldschneider I. Demonstration of large-scale migration of cortical thymocytes to peripheral lymphoid tissues in cyclosporin A-treated rats. J Exp Med 1993;178:285-296.
43. Leclerq G, Plum J, Nandi D, DeSmedt M, Allison JP. Intrathymic differentiation of V gamma 3T cells. J Exp Med 1993;178:309-315.
44. Jenkins MK, Schwartz RH, Pardoll DM. Effects of cyclosporine A on T cell development and clonal deletion. Science 1988;241:1655-1657.
45. Shi Y, Sahai BM, Green DR. Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature 1989;339:625-626.
46. Sentman CL, Shutter JR, Hockenberry D, Kanagawa O, Korsmeyer S. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991;67:879-888.
47. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK 506. Immunol Today 1992;13:136-142.
48. Hess AD, Horwitz LR, Laulis MK. Cyclosporine induced syngeneic graft-vs-host disease: prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens. Clin Immunol Immunopathol 1993;69: 341-350.
49. Siegel RM, Katsumata M, Komori S. Mechanisms of autoimmunity in the context of T-cell tolerance: insights from natural and transgenic animal model systems. Immunol Rev 1990;118:165-192.
50. Hammerling GJ, et al. Non-deletional mechanisms of peripheral and central tolerance: studies with transgenic mice with tissue-specific expression of a foreign MHC class I antigen. Immunol Rev 1991;122:46-67.
51. Fischer AC, Beschorner WE, Hess AD. Requirements for the induction and adoptive transfer of cyclosporine-induced syngeneic graft-vs-host disease. J Exp Med 1989;169:1031-1041.
52. Hess AD, Fischer AC, Horwitz LR. Cyclosporine-induced autoimmunity: critical role of autoregulation in the prevention of major histocompatibility class II-dependent autoaggression. Transplant Proc 1993;25:2811-2813.
53. Fischer AC, Laulis MK, Horwitz L, Beschorner WE, Hess AD. Host-resistance to cyclosporine induced syngeneic graft-vs-host disease. J Immunol 1989;143:827-832.
54. Jones RJ, Hess AD, Mann RB, Piantadosi S, Vogelsang GB, Farmer ER. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989;1:754-757.
55. Hess AD, Fischer AC, Horwitz L, Bright EC, Laulis MK. Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-vs-host disease. J Immunol 1994;153:400-411.
56. Qin S, et al. "Infectious" transplantation tolerance. Science 1993;259:974-977.
57. Pearce NW, Berger MF, Gurley KE, Spinelli A, Hall BM. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Transplantation 1993;55:380-389.
58. Zhang J, Medaer R, Stinissen P. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 1993;261:1451-1453.
59. Howard M, O'Garra A. Biological properties of interleukin 10. Immunol Today 1992;13:198-200.
60. Offner H, et al. Increased severity of experimental autoimmune encephalomyelitis in rats tolerized as adults but not neonatally to a protective TcR Vβ8 CDR2 idiotope. J Immunol 1995;154:928-934.
61. Jenkins MK, Miller RA. Memory and anergy: challenges to traditional models of T lymphocyte differentiation. FASEB J 1993;6:2428-2433.
62. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion vs. functional clonal inactivation. Annu Rev Immunol 1989;7:445-481.
63. Hiruma K, Gress RE. Cyclosporine A and peripheral tolerance. J Immunol 1992;149:1539-1547.
64. Vanier LE, Prud'homme GJ. Cyclosporin A markedly enhances superantigen-induced peripheral T-cell deletion and inhibits anergy induction. J Exp Med 1992;176:37-46.
65. Fischer AC, Hess AD. Age related factors in cyclosporine-induced syngeneic graft-vs-host disease: regulatory role of marrow derived T lymphocytes. J Exp Med 1990;172:85-94.
66. Ben-Nunn AH, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with a T lymphocyte line reactive against myelin basic protein. Nature 1981;292:60-63.
67. Acha-Orbea H, et al. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 1988;54:263-273.
68. Singer PA, Theofilopoulos AN. T cell receptor Vβ repertoire expression in murine models of SLE. Immunol Rev 1990;118:102-127.
69. Gutierrez-Ramos JC, et al. Insights into autoimmunity: from classical models to current perspectives. Immunol Rev 1990;118:73-101.
70. Heber-Katz E, Acha-Orbea H. The V-region hypothesis: evidence from autoimmune encephalomyelitis. Immunol Today 1989;10:64-67.
71. Smith LR, Kono DH, Kammuller ME. Vβ repertoire in rats and implications for endogenous superantigens. Eur J Immunol 1992;22:641-645.
72. von Boehmer H. The developmental biology of T lymphocytes. Annu Rev Immunol 1988;6:309-376.
73. Hess A, Ruvolo P, Fischer A, Horwitz L, Bright E, Thoburn C. Characterization of the Vα/Vβ autoreactive T cell repertoire in syngeneic graft-vs-host disease. Transplant Proc 1997;29:709-711.
74. Hess AD, Horwitz LR, Laulis MK. Cyclosporine induced syngeneic graft-vs-host disease: recognition of self MHC class II antigens in vivo. Transplant Proc 1993;25:1218-1221.
75. Bryson JS, Carwood BE, Kaplan AM. Relationship of cyclosporine A-mediated inhibition of clonal deletion and development of syngeneic graft-vs-host disease. J Immunol 1991;147:391-397.
76. Babock S, Niswender K, Wilson DB, Bellgrau D. Cyclosporine-induced autoimmunization in rats carrying thymus allografts. Transplantation 1990;50:1278-1281.
77. Woodland DL, Blackman MA. How do T-cell receptors, MHC molecules and superantigens get together? Immunol Today 1993;14:208-211.
78. Malcherek G, Gnau V, Jung G, Rammensee HG, Melms A. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex class II molecules. J Exp Med 1995;181:527-530.
79. Freisewinkel IM, Schench K, Koch N. The segment of the invariant chain that is critical for association with major histocompatibility complex class II molecules contains the sequence of a peptide eluted from class II polypeptides. Proc Natl Acad Sci USA 1993;90:9703-9707.
80. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993;178:27-38.
81. Hess A, Thoburn C, Bright E, Horwitz L. Specificity of effector mechanisms in syngeneic graft-vs-host disease: recognition of the MHC class II invariant chain peptide (CLIP). Transplant Proc 1997;29:725-727.
82. Hess AD, Bright EC, Thoburn C, Vogelsang GB, Jones RJ, Kennedy MJ. Specificity and antitumor activity of effector T lymphocytes in autologous graft-vs-host disease: role of the MHC class II invariant chain peptide. Blood 1997;89:2203-2209.
83. Ericson ML, Sundstrom M, Sansom DM, Charron DJ. Mutually exclusive binding of peptide and invariant chain to major histocompatibility complex class II antigens. J Biol Chem 1994;269:26531-26538.
84. Kersey JH, et al. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N Engl J Med 1987;317:461-469.
85. Philip T, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493-1499.
86. Horowitz MM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-563.
87. Weiden PL, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;300:1068-1073.
88. Fuchs EJ, Bedi A, Jones RJ, Hess AD. Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res 1995;55:463-466.
89. Geller RB, et al. Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 1989;74:1165-1171.
90. Hess AD, Noga SJ. Cyclosporine-induced syngeneic graft-versus-host disease: an immunotherapeutic approach after autologous bone marrow transplantation. Int J Cell Cloning 1992;10 (Suppl 1):179-182.
91. Noga SJ, Horwitz L, Kim H, Laulis MK, Hess AD. γ-Interferon potentiates the anti-tumor effect of cyclosporine-induced autoimmunity. J Hematother 1992;1:75-84.
92. Hess AD, Kennedy MJ, Ruvolo PP, Vogelsang GB, Jones RJ. Antitumor activity of syngeneic/autologous graft-vs-host disease. Ann New York Acad Sci 1995;770:189-202.
93. Jones RJ, et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989;1:754-757.
94. Jones RJ, Vogelsang GB, Ambinder RF, Santos GW, Hess AD. Autologous marrow transplantation (ABMT) with cyclosporine (CsA)-induced autologous graft-versus-host disease (GVHD) for relapsed aggressive non-Hodgkin's lymphoma (NHL). Blood 1991;78:287 (Abstract).
95. Yeager AM, et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992;79:3031-3035.
96. Kennedy MJ, et al. Phase I trial of interferon-gamma to potentiate cyclosporine A-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1994;12:249-257.
97. Kennedy MJ, Vogelsang GB, Jones RJ, Hess AD. Post transplant immunotherapy by induction of autologous GVHD. Proceedings of the Symposium on Autologous Marrow and Blood Transplantation. September 1996; Arlington, Texas, USA. Kluge Carden Jennings Inc. Charlottesville, VA 1997 (In press).
98. Dale BM, Atkinson K, Kotasek D, Biggs JC, Sage RE. Cyclosporine-induced graft-versus-host disease in two patients receiving syngeneic bone marrow transplants. Transplant Proc 1989;21:3816-3817.
99. Carella AM, Gaozza E, Piatti G. Induction of graft-versus-host disease (GVHD) after ABMT for high risk ALL in first CR and second chronic phase of chronic myeloid leukemia. Exp Hematol 1990;18:684 (Abstract).
100. Ratanatharathorn V, et al. Phase I study of alpha interferon augmentation of cyclosporine-induced graft-vs-host disease in recipients of autologous bone marrow transplantation. Bone Marrow Transplant 1994;13:625-631.
101. Ruvolo P, et al. Cyclosporine-induced autologous graft-versus-host disease: assessment of cytocytic effector mechanisms and the Vβ T cell receptor repertoire. Transplant Proc 1995;27:1363-1365.
102. Vogelsang GB, Hess AD, Altomonte V, Bitton R, Horn T, Jones RJ. Interferon augmentation of autologous graft-vs-host disease (GVHD). Blood 1996;88(Suppl):129 (Abstract).